Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Citizens JMP raised the firm’s price target on Evolent Health (EVH) to $13 from $12 and keeps an Outperform rating on the shares. Evolent’s Q4 ...

Full Year 2024 Results Key Financial Results Revenue: US$2.55b (up 30% from FY 2023).

Evolent Health Inc. (EVH) has disclosed a new risk, in the Technology category. Evolent Health Inc. faces significant risks associated with its ...

Oppenheimer analyst Michael Wiederhorn maintained a Buy rating on Evolent Health (EVH – Research Report) today and set a price target of ...

Welcome to the Evolent earnings conference call for the fourth quarter and year ended December 31, 2024. All participants ...

Evolent Health, Inc. ( NYSE: EVH) Q4 2024 Earnings Conference Call February 20, 2025 5:00 PM ET Seth Frank - Vice President, Investor Relations Seth Blackley - Chief Executive Officer John Johnson - ...

Discover key insights from Evolent Health's Q4 2024 earnings call, focusing on 30% revenue growth, contract renegotiations, projections for 2025, ...

Healthcare solutions company Evolent Health (NYSE:EVH) fell short of the market’s revenue expectations in Q4 CY2024, but ...

Evolent Health (EVH) delivered earnings and revenue surprises of 0% and 1.48%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

The healthcare technology company posted adjusted earnings per share of -$0.02 for Q4, missing the consensus estimate of $0.07. Revenue came in at $646.5 million, below analyst projections of $652.2 ...